Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Bought by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC lifted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 145.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,229,292 shares of the company’s stock after acquiring an additional 729,292 shares during the period. Eliem Therapeutics comprises approximately 3.3% of Ally Bridge Group NY LLC’s holdings, making the stock its 13th largest holding. Ally Bridge Group NY LLC’s holdings in Eliem Therapeutics were worth $6,257,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in ELYM. Rhumbline Advisers bought a new stake in Eliem Therapeutics during the second quarter valued at $59,000. SG Americas Securities LLC acquired a new position in shares of Eliem Therapeutics in the 3rd quarter valued at about $60,000. Valence8 US LP bought a new stake in shares of Eliem Therapeutics during the 3rd quarter valued at about $61,000. Dimensional Fund Advisors LP acquired a new stake in Eliem Therapeutics during the second quarter worth about $89,000. Finally, Chicago Partners Investment Group LLC bought a new position in Eliem Therapeutics in the third quarter worth about $81,000. 69.76% of the stock is currently owned by institutional investors.

Eliem Therapeutics Stock Up 5.9 %

Shares of ELYM stock opened at $3.22 on Thursday. The company has a market cap of $95.80 million, a P/E ratio of -5.74 and a beta of -0.39. The business has a 50 day moving average of $4.69 and a two-hundred day moving average of $6.49. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.